



Media Release

April 10, 2026

Idorsia issues invitation to the 2026 Annual General Meeting of Shareholders

Allschwil, Switzerland – April 10, 2026

Idorsia Ltd (SIX: IDIA) today issued the invitation to the upcoming Annual General Meeting (AGM) of Shareholders on behalf of the Board of Directors. The meeting to approve the Annual Report of the year ending December 31, 2025, will be held on Wednesday, May 6, 2026, at 14.00 CEST at the Congress Center, Messe Basel, Switzerland.

Notes to Shareholders

The invitation was published in the Swiss Official Gazette of Commerce (Schweizerisches Handelsamtsblatt) today and will be distributed to Shareholders by post. It is also available, together with the company's Annual Report, at www.idorsia.com/agm.

In order to attend and vote at the AGM, shareholders must be registered in the company's shareholder register by April 27, 2026, 17:00 CEST, at the latest.

Notes to the editor

Agenda for the AGM 2026

1. Annual reporting 2025
 - 1.1 Vote on Annual Report 2025, Consolidated Financial Statements 2025, and Statutory Financial Statements 2025
 - 1.2 Consultative vote on the Compensation Report 2025
 - 1.3 Consultative vote on the Sustainability Report 2025
2. Appropriation of available earnings
3. Discharge of the Board of Directors and of the Executive Committee
4. Board elections
 - 4.1 (Re-)election of members of the Board of Directors
 - 4.2 Re-election of the Chair of the Board of Directors
 - 4.3 (Re-)election of members of the Nominating, Governance & Compensation Committee
5. Vote on Board compensation and Executive Committee compensation
 - 5.1 Vote on Board compensation for the 2026–2027 term of office
 - 5.2 Vote on Executive Committee compensation for 2027
6. Re-election of the Independent Proxy
7. Re-election of the statutory auditors

About Idorsia

The purpose of Idorsia is to discover, develop and commercialize innovative medicines to help more patients. To achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core.

Headquartered near Basel, Switzerland – a European biotech hub – Idorsia has a highly experienced team of dedicated professionals, covering all disciplines from bench to bedside; QUVIVIQ™ (daridorexant), a different kind of insomnia treatment with the potential to revolutionize this mounting public health concern; strong partners to maximize the value of our portfolio; a promising in-house development pipeline; and a specialized drug discovery engine focused on small-molecule drugs that can change the treatment paradigm for many patients. Idorsia is listed on the SIX Swiss Exchange (ticker symbol: IDIA).



For further information, please contact:

Investor & Media Relations

Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil

+41 58 844 10 10

investor.relations@idorsia.com - media.relations@idorsia.com - www.idorsia.com

The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "intend", "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs, business development activities and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.